aTyr Pharma. has been granted a patent for antibodies that specifically target human neuropilin-2 (NRP2) polypeptides. These antibodies can modulate NRP2 interactions and downstream signaling, offering potential therapeutic applications for diseases associated with NRP2. The patent details specific sequences for the antibody’s variable regions. GlobalData’s report on aTyr Pharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on aTyr Pharma, NSAID cancer drugs was a key innovation area identified from patents. aTyr Pharma's grant share as of July 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.
Antibodies targeting human neuropilin-2 for therapeutic use
The granted patent US12065495B2 outlines a therapeutic composition that includes at least one antibody or an antigen-binding fragment specifically targeting the human neuropilin-2 (NRP2) polypeptide. The composition is characterized by its binding to an epitope located in the neuropilin A2 domain of NRP2, with defined heavy and light chain variable region sequences. The claims detail specific complementary determining regions (CDRs) for both the heavy and light chains, identified by specific sequence IDs. The therapeutic composition is designed to antagonize the interaction between NRP2 and plexin receptors or semaphorin 3F (SEMA 3F), while preserving the binding activity with VEGFR3 or VEGF-C.
Further claims specify the nature of the antibodies, which may include various immunoglobulin classes such as IgA, IgD, IgE, IgG, and IgM, with options for high or low effector functions. The patent also encompasses monoclonal antibodies, humanized antibodies, and various formats such as Fv fragments and nanobodies. The composition is required to have a high purity level and be free from aggregates and endotoxins. Additionally, it is formulated as a sterile, injectable solution suitable for multiple administration routes. The therapeutic composition may also include additional agents, such as cancer immunotherapy agents or chemotherapeutic agents, enhancing its potential application in therapeutic settings.
To know more about GlobalData’s detailed insights on aTyr Pharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
